The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis
Open accessAbstract
Objective: To determine the diagnostic accuracy of serological tests for coronavirus disease-2019 (covid-19). Design: Systematic review and meta-analysis. Data sources: Medline, bioRxiv, and medRxiv from 1 January to 30 April 2020, using subject headings or subheadings combined with text words for the concepts of covid-19 and serological tests for covid-19. Eligibility criteria and data analysis: Eligible studies measured sensitivity or specificity, or both of a covid-19 serological test compared with a reference standard of viral culture or reverse transcriptase polymerase chain reaction. Studies were excluded with fewer than five participants or samples. Risk of bias was assessed using quality assessment of diagnostic accuracy studies 2 (QUADAS-2). Pooled sensitivity and specificity were estimated using random effects bivariate meta-analyses. Main outcome measures: The primary outcome was overall sensitivity and specificity, stratified by method of serological testing (enzyme linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), or chemiluminescent immunoassays (CLIAs)) and immunoglobulin class (IgG, IgM, or both). Secondary outcomes were stratum specific sensitivity and specificity within subgroups defined by study or participant characteristics, including time since symptom onset. Results: 5016 references were identified and 40 studies included. 49 risk of bias assessments were carried out (one for each population and method evaluated). High risk of patient selection bias was found in 98% (48/49) of assessments and high or unclear risk of bias from performance or interpretation of the serological test in 73% (36/49). Only 10% (4/40) of studies included outpatients. Only two studies evaluated tests at the point of care. For each method of testing, pooled sensitivity and specificity were not associated with the immunoglobulin class measured. The pooled sensitivity of ELISAs measuring IgG or IgM was 84.3% (95% confidence interval 75.6% to 90.9%), of LFIAs was 66.0% (49.3% to 79.3%), and of CLIAs was 97.8% (46.2% to 100%). In all analyses, pooled sensitivity was lower for LFIAs, the potential point-of-care method. Pooled specificities ranged from 96.6% to 99.7%. Of the samples used for estimating specificity, 83% (10 465/12 547) were from populations tested before the epidemic or not suspected of having covid-19. Among LFIAs, pooled sensitivity of commercial kits (65.0%, 49.0% to 78.2%) was lower than that of non-commercial tests (88.2%, 83.6% to 91.3%). Heterogeneity was seen in all analyses. Sensitivity was higher at least three weeks after symptom onset (ranging from 69.9% to 98.9%) compared with within the first week (from 13.4% to 50.3%). Conclusion: Higher quality clinical studies assessing the diagnostic accuracy of serological tests for covid-19 are urgently needed. Currently, available evidence does not support the continued use of existing point-of-care serological tests. Study registration: PROSPERO CRD42020179452.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Zhang, W., Du, R.-H., Li, B., Zheng, X.-S., Yang, X.-L., Hu, B., Wang, Y.-Y., Xiao, G.-F., Yan, B., Shi, Z.-L., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1729071 · Cited by 1,799
Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., Sun, R., Wang, Y., Hu, B., Chen, W., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25727 · Cited by 1,771
Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo, L., Ren, L., Yang, S., Xiao, M., Chang, D., Yang, F., Dela Cruz, C. S., Wang, Y., Wu, C., Xiao, Y., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa310 · Cited by 1,587
Cited by
Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 “long haulers”
Graham, E. L., Clark, J. R., Orban, Z. S., Lim, P. H., Szymanski, A. L., Taylor, C., DiBiase, R. M., Jia, D. T., Balabanov, R., Ho, S. U., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51350 · Cited by 693
Meyerowitz-Katz, G., & Merone, L. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.1464 · Cited by 566
Torrente-Rodríguez, R. M., Lukas, H., Tu, J., Min, J., Yang, Y., Xu, C., Rossiter, H. B., & Gao, W. (2020) · Matter · doi:10.1016/j.matt.2020.09.027 · Cited by 490
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 443
COVID-19: Discovery, diagnostics and drug development
Asselah, T., Durantel, D., Pasmant, E., Lau, G., & Schinazi, R. F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.031 · Cited by 437
Safiabadi Tali, S. H., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi-Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 405
SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis
Rostami, A., Sepidarkish, M., Leeflang, M. M. G., Riahi, S. M., Nourollahpour Shiadeh, M., Esfandyari, S., Mokdad, A. H., Hotez, P. J., & Gasser, R. B. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.10.020 · Cited by 369
Rahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 289
Emerging Telemedicine Tools for Remote COVID-19 Diagnosis, Monitoring, and Management
Lukas, H., Xu, C., Yu, Y., & Gao, W. (2020) · ACS Nano · doi:10.1021/acsnano.0c08494 · Cited by 265
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Chen, X., Chen, Z., Azman, A. S., Deng, X., Sun, R., Zhao, Z., Zheng, N., Chen, X., Lu, W., Zhuang, T., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00026-7 · Cited by 239
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252617 · Cited by 246
Oved, K., Olmer, L., Shemer-Avni, Y., Wolf, T., Supino-Rosin, L., Prajgrod, G., Shenhar, Y., Payorsky, I., Cohen, Y., Kohn, Y., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100651 · Cited by 129
“Numerous serology assays have been developed for SARS-CoV-2 with considerable variation in underlying technology, ease of use, cost, and performance [1].”
Excess mortality in england and wales during the first wave of the COVID-19 pandemic
Kontopantelis, E., Mamas, M. A., Deanfield, J., Asaria, M., & Doran, T. (2021) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2020-214764 · Cited by 121
Coppock, H., Gaskell, A., Tzirakis, P., Baird, A., Jones, L., & Schuller, B. (2021) · BMJ Innovations · doi:10.1136/bmjinnov-2021-000668 · Cited by 108
Wang, Y., Zheng, J., Islam, M. S., Yang, Y., Hu, Y., & Chen, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59534 · Cited by 71
Cao, L., & Liu, Q. (2022) · doi:10.1101/2022.08.22.22279022 · Cited by 49
Metadata
- Authors
- Lisboa Bastos, M., Tavaziva, G., Abidi, S. K., Campbell, J. R., Haraoui, L.-P., Johnston, J. C., Lan, Z., Law, S., MacLean, E., Trajman, A., Menzies, D., Benedetti, A., & Ahmad Khan, F.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2020-07-01
- Volume
- 370
- Pages
- m2516
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3038707046
- Cited by
- 832
- References
- 53
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.